Insmed, Inc. (NASDAQ:INSM) Given Average Rating of “Buy” by Analysts

Insmed, Inc. (NASDAQ:INSM) has been assigned an average rating of “Buy” from the twenty-five brokerages that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, twenty-two have issued a buy rating and two have given a strong buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $213.2273.

INSM has been the subject of a number of research reports. Mizuho boosted their price target on Insmed from $204.00 to $206.00 and gave the company an “outperform” rating in a report on Wednesday, March 25th. HC Wainwright boosted their price target on Insmed from $230.00 to $245.00 and gave the company a “buy” rating in a report on Thursday, March 26th. Guggenheim reiterated a “buy” rating and issued a $230.00 price target on shares of Insmed in a report on Thursday, April 16th. Morgan Stanley upgraded Insmed from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $166.00 to $212.00 in a report on Monday, March 30th. Finally, Jefferies Financial Group initiated coverage on Insmed in a report on Monday, March 16th. They issued a “buy” rating and a $228.00 price target for the company.

Insiders Place Their Bets

In other Insmed news, insider Michael Alexander Smith sold 19,638 shares of the company’s stock in a transaction on Monday, March 30th. The stock was sold at an average price of $150.98, for a total transaction of $2,964,945.24. Following the completion of the sale, the insider owned 51,871 shares in the company, valued at $7,831,483.58. This represents a 27.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Roger Adsett sold 88,060 shares of the company’s stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $164.63, for a total value of $14,497,317.80. Following the sale, the chief operating officer owned 106,810 shares of the company’s stock, valued at approximately $17,584,130.30. This represents a 45.19% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 179,777 shares of company stock worth $28,252,720 over the last 90 days. Company insiders own 2.10% of the company’s stock.

Institutional Trading of Insmed

Hedge funds have recently bought and sold shares of the stock. CoreCap Advisors LLC purchased a new stake in shares of Insmed during the 4th quarter valued at $27,000. Reflection Asset Management purchased a new stake in shares of Insmed during the 4th quarter valued at $30,000. GraniteShares Advisors LLC purchased a new stake in shares of Insmed during the 4th quarter valued at $30,000. CIBC Private Wealth Group LLC lifted its holdings in shares of Insmed by 42.1% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 53 shares during the last quarter. Finally, Raiffeisen Bank International AG purchased a new stake in shares of Insmed during the 4th quarter valued at $32,000.

Insmed Price Performance

Shares of NASDAQ INSM opened at $133.26 on Monday. The company has a debt-to-equity ratio of 0.76, a quick ratio of 3.54 and a current ratio of 3.83. The firm has a market capitalization of $28.76 billion, a price-to-earnings ratio of -20.79 and a beta of 0.90. The stock has a 50 day moving average price of $147.89 and a 200 day moving average price of $166.24. Insmed has a 52-week low of $63.81 and a 52-week high of $212.75.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.47). The firm had revenue of $263.84 million during the quarter, compared to analysts’ expectations of $263.97 million. Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. The firm’s revenue for the quarter was up 152.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.32) EPS. Sell-side analysts expect that Insmed will post -2.51 earnings per share for the current year.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.